Galmed Pharmaceuticals Ltd Quick Ratio (GLMD) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Galmed Pharmaceuticals Ltd   (NASDAQ: GLMD)

Galmed Pharmaceuticals Ltd 's Quick Ratio

GLMD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 5.9 below Galmed Pharmaceuticals Ltd average.

Within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Quick Ratio than Galmed Pharmaceuticals Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 425 to 482.

Explain Quick Ratio?
How much Cash & cash equivalents GLMD´s has?
What are GLMD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLMD Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 28.78 % 13.76 % 55.79 % 30.92 % -19.28 %
Y / Y Cash & cash equivalent Change 17.22 % 24.26 % 108.98 % 18.43 % 20.24 %
Quick Ratio MRQ 5.9 7.71 8.48 6.38 6.48
GLMD's Total Ranking # 482 # 425 # # #
Seq. Current Liabilities Change 26.54 % 2.11 % -14.9 % 17.13 % 11.78 %
Seq. Cash & cash equivalent Change -3.11 % -7.2 % 13.06 % 15.3 % 2.71 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 143
Healthcare Sector # 225
Overall Market # 482


Quick Ratio Statistics
High Average Low
31.09 9.7 4.46
(Dec 31 2018)   (Dec 31 2022)




Financial Statements
Galmed Pharmaceuticals Ltd 's Current Liabilities $ 3 Millions Visit GLMD's Balance sheet
Galmed Pharmaceuticals Ltd 's Cash & cash equivalent $ 18 Millions Visit GLMD's Balance sheet
Source of GLMD's Sales Visit GLMD's Sales by Geography


Cumulative Galmed Pharmaceuticals Ltd 's Quick Ratio

GLMD's Quick Ratio for the trailling 12 Months

GLMD Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 30.46 % 14.12 % 4.03 % -15.52 % -25.85 %
Y / Y Cash & cash equivalent TTM Growth 35.5 % 37.14 % 37.08 % 17.18 % 17.86 %
Quick Ratio TTM 7.01 7.23 7.07 6.56 6.75
Total Ranking TTM # 2677 # 3275 # # #
Seq. Current Liabilities TTM Growth 6.88 % 3.03 % 9.63 % 8.07 % -6.51 %
Seq. Cash & cash equivalent TTM Growth 3.69 % 5.33 % 18.13 % 5.02 % 4.95 %

Quick ratio ranking by company, industry and sector >> Back to GLMD Financial Strength Comparisons >> Go to Compare GLMD Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q4 2025 to $3.13 millions, cumulative Quick Ratio decreased to 7.01 below the Galmed Pharmaceuticals Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 365 other companies have achieved higher Quick Ratio than Galmed Pharmaceuticals Ltd . While Quick Ratio overall ranking has improved so far to 2677, from total ranking during the twelve months ending third quarter 2025 at 3275.

Explain Quick Ratio?
How much Cash & cash equivalents GLMD´s has?
What are GLMD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 366
Healthcare Sector # 749
Within the Market # 2677


trailing twelve months Quick Ratio Statistics
High Average Low
31.09 9.01 4.46
(Dec 31 2018)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Xbiotech Inc   15.83 $ 125.551  Millions$ 7.929  Millions
Tango Therapeutics Inc   15.83 $ 343.138  Millions$ 21.679  Millions
Mira Pharmaceuticals Inc   15.71 $ 11.030  Millions$ 0.702  Millions
Phio Pharmaceuticals Corp  15.69 $ 21.031  Millions$ 1.340  Millions
Alto Neuroscience Inc   15.58 $ 176.484  Millions$ 11.325  Millions
Veradermics Inc  15.50 $ 141.862  Millions$ 9.152  Millions
Ocular Therapeutix Inc   15.36 $ 737.060  Millions$ 47.989  Millions
Nuvalent Inc   15.05 $ 1,371.952  Millions$ 91.171  Millions
Mereo Biopharma Group Plc  14.66 $ 41.387  Millions$ 2.824  Millions
Bioharvest Sciences Inc   14.57 $ 46.050  Millions$ 3.160  Millions
Immunome Inc   14.55 $ 654.782  Millions$ 44.990  Millions
Eupraxia Pharmaceuticals Inc   14.51 $ 80.563  Millions$ 5.551  Millions
Climb Bio Inc   14.47 $ 101.080  Millions$ 6.984  Millions
Synlogic Inc   14.41 $ 14.668  Millions$ 1.018  Millions
Cervomed Inc   14.35 $ 20.864  Millions$ 1.454  Millions
Bicara Therapeutics Inc   14.33 $ 414.801  Millions$ 28.949  Millions
Tyra Biosciences Inc   14.15 $ 256.003  Millions$ 18.094  Millions
Rezolute Inc   14.09 $ 167.858  Millions$ 11.912  Millions
Cogent Biosciences Inc   14.08 $ 900.765  Millions$ 63.953  Millions
Keros Therapeutics Inc   14.08 $ 287.415  Millions$ 20.414  Millions
Amylyx Pharmaceuticals Inc   13.97 $ 316.979  Millions$ 22.688  Millions
Oric Pharmaceuticals Inc   13.79 $ 281.488  Millions$ 20.417  Millions
Vtv Therapeutics Inc   13.39 $ 88.932  Millions$ 6.641  Millions
Agios Pharmaceuticals Inc   13.39 $ 854.425  Millions$ 63.814  Millions
Vera Therapeutics Inc   13.37 $ 714.589  Millions$ 53.455  Millions
Chemocentryx Inc.  13.22 $ 0.736  Millions$ 0.056  Millions
Dianthus Therapeutics Inc   13.16 $ 404.295  Millions$ 30.732  Millions
Novo Nordisk A  12.96 $ 761.785  Millions$ 58.768  Millions
Rallybio Corporation  12.96 $ 54.736  Millions$ 4.223  Millions
Damora Therapeutics Inc   12.84 $ 257.624  Millions$ 20.066  Millions

Date modified: 2026-08-29T01:15:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.